Primary Objectives
The primary study objectives, in patients with locally advanced, unresectable Stage III NSCLC treated with durvalumab as part of the UK EAP or non-EAP, are:
1. To describe clinical outcomes
2. To describe the patient demographic and clinical characteristics Secondary Objective
1\. To describe treatment patterns of durvalumab
